Drug Profile
Eicosapentaenoic acid/docosahexaenoic acid - Pivotal Therapeutics
Alternative Names: EPA/DHA - Pivotal; PVT-100; VascazenLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pivotal Therapeutics
- Class Antihyperlipidaemics; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Unsaturated fatty acids
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Atherosclerosis
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cardiovascular-disorders in USA (PO, Capsule)
- 05 Sep 2017 Phase-III development is ongoing in Atherosclerosis in France (NCT02582710)
- 05 Jun 2015 Phase-II clinical trials in Atherosclerosis (stabilisation of plaque) in France (PO)